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Dr Anthony Furnary (Portland, Ore). Dr Galbut, you and
your coauthors have presented a nonrandomized series of BITA
and SITA groups and divided them into terciles of EF. Propensity
matching was done using 14 preoperative variables, and both raw
and unmatched were presented. There was a 14-year follow-up in
group I, less than 30%, and no differences in operative or survival
were seen. There were survival differences in the group with 30%
to 50% EF and the group with greater than 50% EF. In the re-
duced group with 30% to 50% EF, there was a 22-year follow-
up and a raw mortality difference of 17% at 10 years, which
amounted to approximately a 5-year difference in median sur-
vival in the unmatched population. Now when the groups were
propensity matched, those numbers decreased from 17% at 10
years to 4% at 10 years and the median survival decreased
from 5 years to approximately 2 years. The number of patients
who are left at the end of the whole thing at 20 years was less
than 5% of the patient population, and there are only 37 matched
patients at 20 years. I do not think we can make any statistically
valid conclusions on those data. In the normal EF group and the
greater than 50% EF group, there was a 28-year follow-up with
a raw mortality difference of approximately 16% at 10 years
and 12% at 20 years, which amounted to a 4.4% difference in me-
dian survival. Now once again when the groups were propensity
matched using those 14 characteristics, the differences were
markedly reduced again from 17% to 7% at 10 years and from
12% to 2% at 20 years, and the median survival was now down
to 7 months when the propensity matching was carried out. So
statistically speaking, as we all know with nonrandomized and
retrospective studies, when there are significant differences in
the raw outcomes that become smaller and smaller with the
more matching and risk adjustment we do, we really have to
look closely at the risk adjustment techniques and the statistical
techniques to find out if there is anything we missed that might
account for the remaining differences. Because retrospective
studies, as you know, cannot prove causality, we have to take
a critical look at that. There are at least 2 variables that may
not have been accounted for in this incredible study that may
have had an impact on long-term survival. The 2 things that I
looked at in your data (and I appreciate the article in advance)
are year of operation and operating surgeon or operating center.
Year of operation is important because the salutary effects of
newer adjunctive treatments that came to the fore over the 22852 The Journal of Thoracic and Cardiovascular Surgyears of this study between 1972 and 1994 on long-term survival
are significant, such as myocardial protection techniques, the ad-
vent of statins, and the use of beta-blockers, angiotensin-convert-
ing enzyme inhibitors, and implantable cardioverter defibrillators
to prolong survival (especially for those with lower EF). The year
of operation might be an important piece to put in there to miti-
gate some of those factors. I have 5 questions for you.
What was the distribution of patients with SITA versus BITA
over time? Were there more patients with a SITA operated on ear-
lier? Obviously you were a pioneer in this area, but what about the
other centers and surgeons? Is it possible that if there were more
SITA cases operated on earlier, some of these adjunctive therapies
might account for some of the differences in those SITA versus
BITA?
Dr Galbut. The article is extensive in the statistical analyses,
which in all valuations are significant, although I agree that the
percentage may not be large as we go up to 20+ years. Many short-
comings exist in this study, all of which were mentioned and al-
luded to in the article, and we are now looking at age. Age is
perhaps the most important factor, where if you follow patients
longer you see the value of the BITA grafting, and I believe it is
greater in the moderately impaired EF group, 30% to 50%, than
in patients with normal EF.
In regard to your specific question, at the time of this study, pri-
marily from 1985 to 1996, all of the surgeons were together in 1
institution, and then as our community changed and our institution
proliferated into several, I can only comment anecdotally about my
colleagues. Currently the majority have gotten away from BITA
grafting. I don’t know if that answers your question, but during
the time from 1985 to 1994, almost every year 45% to 50% of pa-
tients had BITA grafts. It is unusual in that the broad application is
not seen in other institutions, and it was inspired by our group hav-
ing a major interest in this area.
Dr Furnary.Would it be pretty simple to add the year of oper-
ation to your propensity matching?
Dr Galbut. Yes.
Dr Furnary. I think you should try that, and it might mitigate
some of those points that we brought up. Was there any difference
in operating surgeons; so this was 1 center, same surgeons?
Dr Galbut. I do not believe there were major differences. The
overall operative mortalities were low.
Dr Furnary.Were radial arteries used in your practice, and how
did you account for those?
Dr Galbut. Yes. We used them for a short while. Our belief is
that the radial artery is not as advantageous as the in situ right in-
ternal thoracic artery (RITA) graft, and therefore it is easier to con-
struct as an anastomosis, but our group has not used them in any
large number.
Dr Furnary. In severely ischemic patients in whom we oper-
ate with coronary bypass, that often improves EF, and it seems to
me that study categorization by preoperative EF assumes that the
EF does not change, that is, operate on someone with a 30% EF
and postoperatively it goes to 50% or 55%, and they are now
in the category for survival of the 50% EF. Would it be possible
to use postoperative EF rather than preoperative EF for
categorization?
Dr Galbut. It would be great. That is another limitation of the
study, and we accept that.ery c April 2012
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gle Cox regression instead of one for each group, a single Cox re-
gression that would take into account EF as a variable?
Dr Galbut. Late EF?
Dr Furnary. No, even preoperative because we cannot get EF
postoperatively or we do not have it in every patient.
Dr Galbut. Specific EF or the group?
Dr Furnary. One single Cox regression for the entire cohort of
patients, groups I, II, and III, using EF as one of the variables.
Dr Galbut.One of our limitations, because the study goes back
to a group that ended in 1994, is that the data registry has EF only in
3 categories, so it would be hard to say patient 2000 had an EF of
34%, and that is discussed in the article as a major limitation.
Dr Furnary. Final question. Deep sternal wound infection. I
noticed that your group uses skeletonized thoracic arteries, which
is great, and there was no effect on deep sternal wound infection
between bilateral and single. But there are other covariates or co-
factors that also impart an increased risk, and usually bilateral tho-
racic artery grafting with some of those cofactors, such as diabetes,
COPD, immune deficiency, obesity, is what has been shown in the
literature to significantly increase deep sternal wound infection.
Did you do any subanalyses?The Journal of Thoracic and CaDrGalbut. In a prior article presented this year to the American
Heart Association, we looked at diabetes, and within this group
there was no increased incidence.
Dr Furnary. Great. Richard?
DrRichard Shemin (Los Angeles, Calif). An incredible study. I
cannot wait to see the whole article. I assume that the left internal
thoracic artery (LITA) primarily always went to the left anterior
descending (LAD). What was the strategy for the RITA?
Dr Galbut. Excellent question. The LITAwent to the LAD. For
a short while, wewere using the RITA to the LAD and the LITA se-
quentially to circumflex branches. I never believed in that because in
90% of patients, the LITA is the most important and dominant ves-
sel. LITA to the LAD will confer longevity, so that should not be
risked. We wrote an article a couple years ago with Dr Kurlansky,
who looked at where we placed the RITA, and what was noted is
that it did not matter where the RITA was placed, whether it was
to a proximal circumflex like a ramus or an important diagonal or
the right coronary. I started taking the skeletonized RITA through
the transverse sinus to gain length and anastomose it to a circumflex
obtuse marginal branch one in the 1980s. To answer your question,
my strategy, and I think the majority in the article, was to use the
LITA to the LAD and the RITA to whichever artery was the best fit.rdiovascular Surgery c Volume 143, Number 4 853
